ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Randal Weber on Future Treatment Approaches for Patients With Melanoma

Randal S. Weber, MD, FACS
Published: Tuesday, Mar 01, 2016



Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.

Approximately one-third of patients with metastatic melanoma are showing dramatic responses to immunotherapy agents, Weber explains. Though these patients may have previously had a life expectancy of 6 months or less, such therapies are associated with durable remissions lasting several years.

However, Weber says that, in the future, researchers hope to determine which patients will be most likely to respond to these therapies, with either single agents or combination regimens. Additionally, he hopes that immunotherapy drugs could be administered in second-, third-, and fourth-line settings for high-risk patients following locoregional therapy to prolong survival.



Randal S. Weber, MD, FACS, professor, department chair, John Brooks Williams and Elizabeth Williams Distinguished University Chair in Cancer Medicine, Department of Head and Neck Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses future treatment approaches for patients with melanoma.

Approximately one-third of patients with metastatic melanoma are showing dramatic responses to immunotherapy agents, Weber explains. Though these patients may have previously had a life expectancy of 6 months or less, such therapies are associated with durable remissions lasting several years.

However, Weber says that, in the future, researchers hope to determine which patients will be most likely to respond to these therapies, with either single agents or combination regimens. Additionally, he hopes that immunotherapy drugs could be administered in second-, third-, and fourth-line settings for high-risk patients following locoregional therapy to prolong survival.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x